Pfizer buys Amplyx to expand drug-resistant treatment portfolio

Pfizer Inc said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant “superbug” fungal infections in patients with compromised immune systems.

If approved, Amplyx’s lead drug fosmanogepix would be the first new class of antifungal treatments in 20 years. Terms of the deal were not disclosed.

Fungi, like bacteria, can develop the ability to defeat the drugs designed to kill them.